NEWPORT BEACH, Calif.

加利福尼亚州纽波特比奇

,

，

Aug. 19, 2026

2026年8月19日

/PRNewswire/ -- Renata Medical, a privately held medical technology company dedicated to transforming care for children with congenital heart disease (CHD), today announced the close of a $25 million Series D financing round. The round was led by ARCHIMED, a global investment firm focused exclusively on healthcare, with participation from existing investors..

/美通社/ -- 专注于改善先天性心脏病（CHD）患儿护理的私营医疗技术公司Renata Medical今日宣布完成2500万美元的D轮融资。本轮融资由专注于医疗保健领域的全球投资公司ARCHIMED领投，现有投资者也跟投参与。

Proceeds from the financing will support expanded U.S. commercialization efforts for the Minima™ Stent System, entrance into international markets, advancement of the company's pipeline of pediatric-specific CHD technology, and support for continued clinical evidence generation as Minima adoption grows across leading congenital heart programs worldwide..

融资所得将用于支持Minima™支架系统在美国的商业化拓展、进入国际市场、推进公司专用于儿童先天性心脏病（CHD）的技术管线，并随着Minima在全球领先先天性心脏病项目中的采用率不断提升，为持续生成临床证据提供支持。

'Adoption of the Minima™ Stent System has exceeded our expectations since commercial launch in 2024,' said Dustin Armer, Co-founder and Chief Executive Officer of Renata Medical. 'The support and participation of ARCHIMED is further validation of what we are building and of the growing opportunity to transform care for children with congenital heart disease'.

“自2024年商业发布以来，Minima™支架系统的应用超出了我们的预期。”Renata Medical联合创始人兼首席执行官Dustin Armer表示。“ARCHIMED的支持和参与进一步验证了我们所构建的愿景，也印证了为先天性心脏病儿童改变治疗方式的巨大机遇正在增长。”

The Minima™ Stent System is the first balloon expandable growth stent designed specifically for use in neonates, infants, and young children with pulmonary artery stenosis or coarctation of the aorta and received FDA premarket approval in August 2024. In August 2025, the Centers for Medicare & Medicaid Services (CMS) granted the device a New Technology Add-on Payment (NTAP) designation, providing hospitals with additional reimbursement support for the technology..

Minima™支架系统是首款专为患有肺动脉狭窄或主动脉缩窄的新生儿、婴儿及幼儿设计的球囊扩张式生长支架，并于2024年8月获得美国食品药品监督管理局（FDA）的上市前批准。2025年8月，美国医疗保险和医疗补助服务中心（CMS）授予该设备新技术附加支付（NTAP）资格，为医院应用该技术提供额外的报销支持。

'Children born with congenital heart defects have too often been treated with devices built for adults and many face repeat procedures simply because their implants cannot grow with them' said André-Michel Ballester, Managing Partner at ARCHIMED and former CEO of LivaNova. 'Having spent much of my career in cardiovascular devices, I have rarely seen a technology address so clearly an unmet need.

“患有先天性心脏缺陷的儿童往往被迫使用为成人设计的器械进行治疗，许多患儿仅仅因为植入物无法随其生长而不得不反复接受手术。”ARCHIMED的管理合伙人兼LivaNova前首席执行官安德烈-米歇尔·巴莱斯特表示。“我在心血管器械领域度过了职业生涯的大部分时间，很少见到哪项技术能如此明确地满足尚未被满足的临床需求。”

We are proud to back the Renata team as they scale the business and advance a pipeline of purpose-built pediatric therapies.'.

我们自豪地支持Renata团队，助力其业务扩张，并推进一系列专为儿童设计的疗法研发管线。

About Renata Medical

关于雷纳塔医疗

Renata Medical, a Delaware corporation, was founded in 2019 with the focus on creating cardiovascular devices for unmet pediatric needs. Renata is committed to innovating, manufacturing, and selling technology that is purposefully created for pediatric patients worldwide. For more information, visit .

雷纳塔医疗（Renata Medical）是一家特拉华州公司，成立于2019年，专注于开发满足儿科未竟需求的心血管器械。雷纳塔致力于创新、制造和销售专为全球儿科患者量身打造的技术产品。欲了解更多信息，请访问。

www.renatamedical.com

www.renatamedical.com

.

。

About ARCHIMED

关于 ARCHIMED

With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech.

ARCHIMED 是一家领先的投资公司，专注于医疗健康行业，在欧洲、北美和亚洲均设有办公室。其融合了运营、医疗、科学和金融领域的专业知识，使 ARCHIMED 能够成为医疗健康企业的战略与财务合作伙伴。重点关注的领域包括动物与环境健康、生物制药产品、消费者健康、诊断技术、医疗信息技术、生命科学工具与服务以及医疗科技。

ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation..

ARCHIMED 帮助合作伙伴实现国际化、并购、创新以及拓展其产品与服务。ARCHIMED 旗下各类基金的管理规模达 90 亿欧元。自成立之初，ARCHIMED 便通过直接投资及其 EURÊKA 基金会，坚定不移地践行影响力投资。

SOURCE Renata Medical

来源：Renata Medical

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示